Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis

The study population will consist of a total of 30 patients diagnosed with multiple sclerosis, who meet all inclusion criteria and none of the exclusion set and express their agreement to participate in the study by signing the informed consent of those whose results can be clinically evaluable.

Selected patients who consent will be enrolled in the trial and randomized to one of the following groups:

• Group 1 receiving a single intravenous administration of cellular product on Day 0 and placebo infusion on day + 180.
• Group 2 receiving a placebo infusion on day 0 and a single cell product administration on day +180.

Randomization will be 1:1, so that 15 patients will receive the cellular product on Day 0 (Group 1) and 15 patients on day +180 (group 2), always maintaining at all times the double-blind status of the test (patients and researchers).

The bone marrow will be extract from all patients immediately after inclusion in the study, under local anesthesia with sedation. For patients in group 1 autologous mesenchymal cells will be obtained from the bone marrow and infuse immediately after the time necessary for their production. For patients in group 2, bone marrow cells will be frozen for later procedure of mesenchymal cells and their infusion after six months.

Patients will be evaluated by clinical, radiological, and electrophysiological as well as detailed in section 8 corresponding to Development Test and Evaluation of Response.

It is estimated that the inclusion period is approximately 12-18 months, and each patient tracking another twelve months. Therefore the total duration of the study will be about 24 to 30 months from the inclusion of the first patient to completion follow-up period of the last patient included.

Study objectives:

• Main objectives: 1. To evaluate the safety of intravenous infusion of autologous bone marrow mesenchymal cells in multiple sclerosis patients diagnosed by evaluating complications and adverse effects of the therapy itself and study procedures.

• Assessing the difference in the number of lesions on magnetic resonance image with gadolinium, between the groups undergoing treatment at weeks 4, 12 and 24.
• Secondary objectives: 1. To evaluate the feasibility and efficacy of the indication of the treatment by analysis comparative results and exploratory clinical variables of patients at baseline (pretreatment) and at 6 and 12 months follow-up.

• Compare the results of safety, feasibility and efficacy between the administration initial cell therapy treatment (day 0) and that delayed (day +180).

• Evaluating the immunomodulatory effect of treatment by quantifying cell subsets and cytokines, functional analysis of the immune response. Cerebrospinal fluid metabolomic profile of gene expression of the cells present in blood and cerebrospinal fluid, with the aim of identifying new biomarkers with diagnosis of interest, prognosis or monitoring, and potential therapeutic targets that can be derived from it.

• Providing our results to the study proposed by the International Mesenchymal Stem Cell Transplant Study Group under whose directives will be performed the test.

Inclusion criteria

• Patients diagnosed with MS in their inflammatory forms :

• Course outbreaks ( relapsing- remitting ) , who have not responded to at least one year of treatment with one or more of the approved therapies (beta - interferon, glatiramer acetate, natalizumab , mitoxantrone, fingolimod ) , confirmed by one or more of the following criteria:

( ii ) At least one clinically documented outbreak in the past 12 months. ( iii ) At least two clinically documented outbreaks in the last 24 months ( iv ) At least one lesion with gadolinium on MRI performed in the last 12 months.

b . Secondary progressive forms that have not responded to at least one year of treatment with one or more of the approved therapies ( interferon beta , glatiramer acetate, natalizumab , mitoxantrone, fingolimod ) . That meet the following criteria:

( i ) Increase of 1 point or more if baseline EDSS score is less than or equal to 5.0 , or 0.5 point increase if the baseline score is greater than or equal to 5.5, in the last 12 months.

( ii ) at least one clinically documented outbreak or at least one lesion with gadolinium on MRI within the last 12 months.

c . Primary progressive forms that meet the following three criteria:

( i ) Increase of 1 point or more if baseline EDSS score is less than or equal to 5.0 , or 0.5 point increase if the baseline score is greater than or equal to 5.5, in the last 12 months.

( ii ) At least 1 lesion with gadolinium on MRI within the last 12 months. ( iii ) oligoclonal bands in cerebrospinal fluid (CSF) .

2 . Normal laboratory parameters , defined by:

• Leukocytes ≥ 3000
• Neutrophils ≥ 1500
• Platelets ≥ 100,000
• Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤ 2.5 standard range institution
• Creatinine ≤ 2.5 mg / dl

3 . Patients of both sexes aged between 18 and 50.

4 . Disease duration ≥ 2 years and ≤ 10 years.

5 . EDSS (Expanded Disability Status Scale) between 3.0 and 6.5 points.

• Patients give their informed consent for participation in the clinical trial consent.

• Women of childbearing potential must have negative results on a pregnancy test at the time of inclusion in the study and agree to use a medically approved method of contraception while on study

Exclusion criteria

• Any active or chronic infection, including Hepatitis B virus (HBV), Hepatitis C virus (HCV) or HIV .
• Immunosuppressive therapy in the 3 months prior to randomization (including natalizumab and fingolimod ).
• Treatment with interferon beta or glatiramer acetate in the 30 days prior to randomization .
• Corticosteroid therapy in the 30 days prior to randomization.
• Time since last exceeding 60 days prior to randomization outbreak.
• History of malignancy ( basal cell carcinoma of skin and carcinoma in situ are excluded in remission for over a year).
• Life expectancy severely limited by other co - morbidities.
• Previous history of myelodysplasia or hematological disease , or clinically relevant changes currently in the leukocyte count.
• Pregnancy / risk of pregnancy (including refusal to use contraception)
• Renal failure (eGFR <60 mL/min/1.37m2)
• Inability to undergo MRI scans
• Inability to give written informed consent.